Lymphoma Therapy Market Size is projected to reach USD 13.14 Billion by 2029
Lymphoma Therapy Market Share, Analysis Report and Region Forecast 2022 to 2029 | F. Hoffmann La Roche AG, Eli Lilly, Pfizer Inc., Bristol Myers Squibb, AstraZeneca PLC, Bayer AG
/EIN News/ -- Luton, Bedfordshire, United Kingdom, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Lymphoma Therapy Market.
The Global Lymphoma Therapy Market is expected to reach 13.14 Billion at a CAGR of 8.3% during the forecast period 2022-2029.
Non-Hodgkin lymphoma includes Burkitt lymphoma. NHL is a lymphatic system cancer. It manifests when the body produces B cells that are aberrant. These white blood cells, known as lymphocytes, are typically used to combat infections.
The large unmet clinical needs associated with the condition and recent product introductions are anticipated to fuel outstanding growth in the market for lymphoma therapeutics worldwide. NHL medicines dominate the world market for lymphoma treatments. The rising incidence of lymphoma, higher funding from various governments, greater awareness, and quicker regulatory approvals are further reasons that would fuel market expansion. The market would be constrained from growing, however, by expensive medications, a lack of reimbursement, and probable opposition to approved treatments. On the other hand, drug developers would continue to face a significant challenge due to the emergence of resistance to tested treatments. Expanding government R&D spending and rising patient and professional awareness of early lymphoma identification are some of the factors that are projected to propel market expansion. For instance, the National Cancer Institute receives funding from the US Congress to support cancer research and related initiatives.
Get Access Sample Copy of the Lymphoma Therapy Market Strategic Report:
North America accounted for the largest market share in 2022, with market size of USD 3.33 billion. The higher frequency of lymphoma, greater patient awareness of lymphoma therapy, higher rate of adoption of cutting-edge lymphoma therapeutic medications, and higher healthcare expenditure in the region are just a few of the factors that have contributed to the region's dominance in the global market. Additionally, ongoing R&D by major market participants in the form of clinical trials for new medication candidates for the treatment of lymphoma has also helped to increase the market in the area. Europe is anticipated to be the second-most dominating market throughout the projection period, and the area's large share can be attributed to both the high number of people in the region who need treatment and the high usage of sophisticated treatments. Out of all the regions of the worldwide industry, the Asia-Pacific market is anticipated to have the highest CAGR during the forecast period.
Recent Development: -
- Pfizer Inc announced the termination of the Phase 3 randomized, open-label, two-arm study examining the safety and effectiveness of the investigational drug inotuzumab ozogamicin in patients with aggressive CD22 non-Hodgkin lymphoma who have relapsed or are refractory and are not candidates for intensive high-dose chemotherapy.
- The U.S. Food and Drug Administration received a supplemental new drug application from Bayer, the firm said in an announcement (FDA). Additionally, the company has submitted a marketing authorization application to the European Medicines Agency (EMA) for the copanlisib and rituximab cancer therapy combination in the U.S.
- The U.S. Food and Drug Administration (FDA) approved cancer immunotherapy for some lymphomas, according to a statement released by Bristol Myers Squibb. The medicine was given FDA approval as a treatment option for adults with specific non-Hodgkin lymphoma types.
| Report Attribute | Details |
| The revenue forecast in 2029 | 13.14 Billion |
| Growth Rate | CAGR of 8.3% from 2022 to 2029 |
| Base year for estimation | 2021 |
| Historical data | 2017 to 2021 |
| Forecast period | 2022 to 2029 |
| Quantitative units | Revenue in billion and CAGR from 2022 to 2029 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | By Cancer Type, By Therapy Type |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; Japan; India; South Korea; Brazil |
| Key companies profiled | F. Hoffmann La Roche AG, Eli Lilly, Pfizer Inc., Bristol Myers Squibb (BMS), AstraZeneca PLC, Bayer AG, Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, Novartis AG and Others |
Lymphoma Therapy Market - Competitive Landscape
Due to the presence of prominent oncology market rivals and their broad product selection of oncology pharmaceuticals, the competitive landscape in the lymphoma treatment market exhibits rather intense competition. Numerous significant industry players include F. Hoffmann La Roche AG, Eli Lilly, Pfizer Inc., Bristol Myers Squibb, AstraZeneca PLC, Bayer AG, Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, Novartis AG and Others
Trends and Opportunities of the Lymphoma Therapy Market
One of the main drivers anticipated to drive growth in the lymphoma therapy market is the increased incidence of all cancer types, including blood cancers. A significant number of instances of blood cancer are lymphomas, and demand for advanced treatment items is rising. It is essential since a significant part of these malignancies typically do not exhibit clinical symptoms until the disease has advanced. A more severe form of treatment is required at this stage of the disease for greater therapeutic results. During the anticipated period, these factors are anticipated to fuel the growth of the lymphoma treatment market. Enhancing patient outcomes in locations where the disease has advanced and is more challenging to treat is a crucial additional element. In these situations, a more complex and varied course of therapy is typically necessary, which raises the demand for cutting-edge and sophisticated remedies.
Browse Full Lymphoma Therapy Market Report:
Key Market Segments: Lymphoma Therapy Market
Global Lymphoma Therapy Market: By Cancer Type
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (NHL)
Global Lymphoma Therapy Market: By Therapy Type
- Targeted Therapy
- Approved drugs
- Pipeline drugs
- Chemotherapy
- Approved drugs
- Pipeline drugs
- Immunotherapy
- Others
Browse More Reports by Pharma Research Consulting
Hormone Refractory Prostate Cancer Market
Castrate Resistant Prostate Cancer is another name for hormone-refractory prostate cancer. This unusual type of cancer may return even after hormone therapy. It now falls within the umbrella of prostate cancer. Castrate-resistant prostate cancer or hormone-refractory prostate cancer refers to prostate cancer that returns after hormonal therapy. Due to the large unmet clinical need brought on by short survival durations, intensifying HRPCA prevalence, and quickly developing therapeutic adjustments, the global HRPCA market is anticipated to expand at an exceptional rate.
https://pharmaresearchconsulting.com/reports/hormone-refractory-prostate-cancer-market
Hemophilia A and B Recombinant Factor Replacement Therapy Market
Excessive or irregular bleeding is brought on by a group of genetic hereditary diseases known as Hemophilia. It obstructs the process of blood clotting that occurs naturally after an injury. Internal bleeding, either inside the joint or inside the brain, is frequently experienced by patients with severe to moderate Hemophilia. One of its symptoms is bleeding anywhere on the body. Internal bleeding is fatal because it harms the brain and joints, and when it happens inside the joint, it can result in seizures. Males are usually affected with hemophilia because it is transmitted in an X-linked recessive genetic pattern, while females are usually carriers.
Phage Therapy Market
Bacteriophages are viruses, also known as phages, that only and specifically target and destroy bacteria. They are the most common biological creatures in nature and have been shown to effectively fight and remove multi-drug resistant bacteria. A few of the main factors propelling the market for phage therapy include growing bacteriophage use in the food and beverage industry, an increase in cases of food-borne illnesses, intense research and development, the use of bacteriophages to treat particular bacteria, and the rise in antimicrobial resistance.
https://pharmaresearchconsulting.com/reports/phage-therapy-market
Head and Neck Cancer Therapeutics Market
The main market segments for therapies for head and neck cancer are type, end user, regional distribution, and competition. Market segments for different types of treatments are further analyzed regarding disease indication, delivery route, and therapeutic class. Diagnostic techniques and various forms of treatment make up the market's type-based segments. Over the next seven years, it is anticipated that diagnostic methods would dominate the market and generate the largest revenue share due to the growing demand for accurate and timely cancer diagnoses. Early cancer detection is essential because it increases the likelihood of successful treatment, and the industry as a whole benefit from the expansion of this market segment.
https://pharmaresearchconsulting.com/reports/head-and-neck-cancer-therapeutics-market
Irfan Tamboli (Head of Sales) - Exactitudeconsultancy
Phone: + 1704 266 3234
sales@exactitudeconsultancy.com
LinkedIn: https://www.linkedin.com/company/exactitudeconsultancy/
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
